Psilocybin Outperforms Nicotine Patch in Smoking Cessation Study

The latest research suggests that psilocybin, the active compound in certain psychedelic mushrooms, may be more effective than nicotine patches in helping individuals quit smoking when combined with cognitive behavioral therapy (CBT). This significant finding offers hope for the millions of smokers struggling to break free from a habit that contributes to serious health issues.

Currently, over 16 million Americans live with smoking-related illnesses, and approximately 480,000 deaths in the United States each year are attributed to smoking, which affects nearly every organ in the body. Despite the existence of various cessation aids—including nicotine patches, gum, lozenges, and prescription medications like varenicline and bupropion—many smokers continue to relapse. In 2024, around 25.2 million people reported smoking cigarettes, with more than two-thirds of adult smokers expressing a desire to quit, according to the Centers for Disease Control and Prevention (CDC). Yet, fewer than one in ten manage to do so annually.

Researchers at Johns Hopkins University conducted a study involving 82 adult smokers who had previously attempted to quit. The participants were divided into two groups: one group used nicotine patches for a duration of eight to ten weeks, while the other received a single, high dose of psilocybin in a controlled environment monitored by trained facilitators. Both groups engaged in 13 weeks of CBT, a therapeutic approach aimed at helping individuals identify and overcome triggers associated with their addiction.

After six months, the results revealed that participants in the psilocybin group had more than six times the odds of quitting compared to those using nicotine patches. Specifically, 17 participants in the psilocybin group remained smoke-free, contrasted with only four in the patch group. The study findings indicated that those in the psilocybin group smoked approximately 50% fewer cigarettes daily between their target quit date and the six-month follow-up.

This is not the first instance of psilocybin showing potential in smoking cessation. A smaller pilot study with 15 participants demonstrated that two or three psilocybin sessions coupled with CBT led to around 80% abstinence at the six-month mark, with roughly 60% maintaining abstinence for a year or more after treatment. The researchers postulate that psilocybin therapy may offer a novel approach to quitting smoking by altering cognitive processes rather than merely targeting nicotine receptors.

In their report, the researchers stated, “Psilocybin’s lack of direct interaction with nicotinic acetylcholine receptors highlights psychedelic therapy as a unique approach, in which the drug does not directly alter reinforcement or withdrawal.”

Experts not involved in the study have expressed enthusiasm regarding the findings. Megan Piper, director of the University of Wisconsin Center for Tobacco Research and Intervention, commented on NPR’s “All Things Considered,” stating, “It’s been 20 years since we’ve had a new medication to help people quit smoking. We need something novel, and this is definitely a novel approach.”

Nonetheless, the study has its limitations. Notably, there was no placebo group, which means participants were aware of receiving psilocybin, potentially influencing their experiences and expectations. Additionally, the study sample was predominantly highly educated and lacked racial and ethnic diversity, which could affect the generalizability of the results.

“Nevertheless, [the] findings support accelerating development of psychedelic therapies for substance use disorders, including tobacco,” the researchers concluded.

Looking ahead, the research team plans to conduct a larger study to further explore psilocybin’s potential as a smoking cessation tool. They aim to optimize treatment protocols, assess cost-effectiveness, and investigate the feasibility of scaling up this innovative approach to tackle smoking addiction on a broader scale.